vs
Side-by-side financial comparison of LAUREATE EDUCATION, INC. (LAUR) and Bio-Techne (TECH). Click either name above to swap in a different company.
LAUREATE EDUCATION, INC. is the larger business by last-quarter revenue ($541.4M vs $311.4M, roughly 1.7× Bio-Techne). LAUREATE EDUCATION, INC. runs the higher net margin — 31.7% vs 16.4%, a 15.3% gap on every dollar of revenue. On growth, LAUREATE EDUCATION, INC. posted the faster year-over-year revenue change (27.9% vs -1.5%). Over the past eight quarters, LAUREATE EDUCATION, INC.'s revenue compounded faster (40.2% CAGR vs 1.3%).
Laureate Education, Inc. is a company based in Miami, Florida, United States. The firm owns and operates Laureate International Universities, with campuses in Mexico and Peru. The company is publicly traded on the Nasdaq.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
LAUR vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $541.4M | $311.4M |
| Net Profit | $171.6M | $51.0M |
| Gross Margin | 35.8% | 66.9% |
| Operating Margin | 33.2% | 24.2% |
| Net Margin | 31.7% | 16.4% |
| Revenue YoY | 27.9% | -1.5% |
| Net Profit YoY | 83.2% | 126.0% |
| EPS (diluted) | $1.14 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $311.4M | ||
| Q4 25 | $541.4M | $295.9M | ||
| Q3 25 | $400.2M | — | ||
| Q2 25 | $524.2M | $317.0M | ||
| Q1 25 | $236.2M | $316.2M | ||
| Q4 24 | $423.4M | $297.0M | ||
| Q3 24 | $368.6M | $289.5M | ||
| Q2 24 | $499.2M | $306.1M |
| Q1 26 | — | $51.0M | ||
| Q4 25 | $171.6M | $38.0M | ||
| Q3 25 | $34.5M | — | ||
| Q2 25 | $95.1M | $-17.7M | ||
| Q1 25 | $-19.5M | $22.6M | ||
| Q4 24 | $93.6M | $34.9M | ||
| Q3 24 | $85.5M | $33.6M | ||
| Q2 24 | $128.1M | $40.6M |
| Q1 26 | — | 66.9% | ||
| Q4 25 | 35.8% | 64.6% | ||
| Q3 25 | 20.9% | — | ||
| Q2 25 | 39.5% | 62.7% | ||
| Q1 25 | -0.9% | 67.9% | ||
| Q4 24 | 32.0% | 65.3% | ||
| Q3 24 | 22.4% | 63.2% | ||
| Q2 24 | 36.1% | 66.4% |
| Q1 26 | — | 24.2% | ||
| Q4 25 | 33.2% | 18.4% | ||
| Q3 25 | 17.9% | — | ||
| Q2 25 | 36.9% | -7.5% | ||
| Q1 25 | -5.6% | 12.2% | ||
| Q4 24 | 29.3% | 16.0% | ||
| Q3 24 | 19.5% | 13.8% | ||
| Q2 24 | 33.4% | 15.0% |
| Q1 26 | — | 16.4% | ||
| Q4 25 | 31.7% | 12.8% | ||
| Q3 25 | 8.6% | — | ||
| Q2 25 | 18.1% | -5.6% | ||
| Q1 25 | -8.3% | 7.1% | ||
| Q4 24 | 22.1% | 11.7% | ||
| Q3 24 | 23.2% | 11.6% | ||
| Q2 24 | 25.7% | 13.3% |
| Q1 26 | — | $0.32 | ||
| Q4 25 | $1.14 | $0.24 | ||
| Q3 25 | $0.23 | — | ||
| Q2 25 | $0.65 | $-0.11 | ||
| Q1 25 | $-0.13 | $0.14 | ||
| Q4 24 | $0.60 | $0.22 | ||
| Q3 24 | $0.56 | $0.21 | ||
| Q2 24 | $0.83 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $146.7M | $209.8M |
| Total DebtLower is stronger | $73.1M | — |
| Stockholders' EquityBook value | $1.2B | $2.1B |
| Total Assets | $2.2B | $2.6B |
| Debt / EquityLower = less leverage | 0.06× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $209.8M | ||
| Q4 25 | $146.7M | $172.9M | ||
| Q3 25 | $241.0M | — | ||
| Q2 25 | $135.3M | $162.2M | ||
| Q1 25 | $109.8M | $140.7M | ||
| Q4 24 | $91.3M | $177.5M | ||
| Q3 24 | $134.4M | $187.5M | ||
| Q2 24 | $128.8M | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | $73.1M | $260.0M | ||
| Q3 25 | $70.6M | — | ||
| Q2 25 | $78.1M | $346.0M | ||
| Q1 25 | $91.0M | $330.0M | ||
| Q4 24 | $59.0M | $300.0M | ||
| Q3 24 | $129.8M | $300.0M | ||
| Q2 24 | $203.0M | $319.0M |
| Q1 26 | — | $2.1B | ||
| Q4 25 | $1.2B | $2.0B | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | $1.9B | ||
| Q1 25 | $908.5M | $2.0B | ||
| Q4 24 | $959.5M | $2.1B | ||
| Q3 24 | $897.7M | $2.1B | ||
| Q2 24 | $918.0M | $2.1B |
| Q1 26 | — | $2.6B | ||
| Q4 25 | $2.2B | $2.5B | ||
| Q3 25 | $2.1B | — | ||
| Q2 25 | $2.0B | $2.6B | ||
| Q1 25 | $1.9B | $2.6B | ||
| Q4 24 | $1.9B | $2.7B | ||
| Q3 24 | $1.9B | $2.7B | ||
| Q2 24 | $2.1B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | 0.06× | 0.13× | ||
| Q3 25 | 0.06× | — | ||
| Q2 25 | 0.07× | 0.18× | ||
| Q1 25 | 0.10× | 0.16× | ||
| Q4 24 | 0.06× | 0.14× | ||
| Q3 24 | 0.14× | 0.14× | ||
| Q2 24 | 0.22× | 0.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $93.4M | — |
| Free Cash FlowOCF − Capex | $26.4M | — |
| FCF MarginFCF / Revenue | 4.9% | — |
| Capex IntensityCapex / Revenue | 12.4% | — |
| Cash ConversionOCF / Net Profit | 0.54× | — |
| TTM Free Cash FlowTrailing 4 quarters | $263.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $93.4M | — | ||
| Q3 25 | $141.0M | — | ||
| Q2 25 | $74.1M | $98.2M | ||
| Q1 25 | $57.8M | $41.1M | ||
| Q4 24 | $40.7M | $84.3M | ||
| Q3 24 | $118.7M | $63.9M | ||
| Q2 24 | $40.2M | $75.5M |
| Q1 26 | — | — | ||
| Q4 25 | $26.4M | — | ||
| Q3 25 | $122.8M | — | ||
| Q2 25 | $60.8M | $93.3M | ||
| Q1 25 | $53.2M | $31.0M | ||
| Q4 24 | $3.4M | $77.5M | ||
| Q3 24 | $110.7M | $54.7M | ||
| Q2 24 | $29.5M | $57.5M |
| Q1 26 | — | — | ||
| Q4 25 | 4.9% | — | ||
| Q3 25 | 30.7% | — | ||
| Q2 25 | 11.6% | 29.4% | ||
| Q1 25 | 22.5% | 9.8% | ||
| Q4 24 | 0.8% | 26.1% | ||
| Q3 24 | 30.0% | 18.9% | ||
| Q2 24 | 5.9% | 18.8% |
| Q1 26 | — | — | ||
| Q4 25 | 12.4% | — | ||
| Q3 25 | 4.5% | — | ||
| Q2 25 | 2.5% | 1.5% | ||
| Q1 25 | 2.0% | 3.2% | ||
| Q4 24 | 8.8% | 2.3% | ||
| Q3 24 | 2.2% | 3.2% | ||
| Q2 24 | 2.1% | 5.9% |
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 4.09× | — | ||
| Q2 25 | 0.78× | — | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | 0.43× | 2.42× | ||
| Q3 24 | 1.39× | 1.90× | ||
| Q2 24 | 0.31× | 1.86× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LAUR
| Mexico Segment | $275.9M | 51% |
| Peru Segment | $265.5M | 49% |
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
